Genmab A/S annual return on equity
2023
2024
2025
Genmab A/S Return on Equity (ROE) Growth & History (GMAB)
Genmab A/S's return on equity was 17.53% for fiscal 2025.
View full Genmab A/S company overviewGenmab A/S annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 17.53% | −5.53 pp |
| 2024 | 2024-12-31 | 23.07% | +8.41 pp |
| 2023 | 2023-12-31 | 14.65% | — |
Genmab A/S quarterly return on equity
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 5.21% | −1.23 pp |
| Q1 2026 | 2026-03-31 | 0.92% | — |
| Q4 2025 | 2025-12-31 | 0.53% | — |
| Q3 2025 | 2025-09-30 | 7.26% | — |
| Q2 2025 | 2025-06-30 | 6.44% | — |
Genmab A/S return on equity trends
Between the periods ended 2023-12-31 and 2025-12-31, Genmab A/S's return on equity increased from 14.65% to 17.53%, a change of +2.88 percentage points. The latest reported quarter, Q2 2026, shows 5.21%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Genmab A/S source filings ↗